Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
448 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hepatitis C - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape. Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 20, 16, 1, 50, 47 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 21 molecules, respectively. Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 6 Hepatitis C - Overview 7 Hepatitis C - Therapeutics Development 8 Hepatitis C - Therapeutics Assessment 29 Hepatitis C - Companies Involved in Therapeutics Development 39 Hepatitis C - Drug Profiles 68 Hepatitis C - Dormant Projects 394 Hepatitis C - Discontinued Products 411 Hepatitis C - Product Development Milestones 416 Appendix 429
List of Tables
Number of Products under Development for Hepatitis C, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 Products under Development by Companies, H2 2017 (Contd..7), H2 2017 Products under Development by Companies, H2 2017 (Contd..8), H2 2017 Products under Development by Universities/Institutes, H2 2017 Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Hepatitis C - Pipeline by AbbVie Inc, H2 2017 Hepatitis C - Pipeline by AIMM Therapeutics BV, H2 2017 Hepatitis C - Pipeline by Akshaya Bio Inc, H2 2017 Hepatitis C - Pipeline by Amarillo Biosciences Inc, H2 2017 Hepatitis C - Pipeline by Amarna Therapeutics BV, H2 2017 Hepatitis C - Pipeline by ARA Healthcare Pvt Ltd, H2 2017 Hepatitis C - Pipeline by Aviragen Therapeutics Inc, H2 2017 Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2017 Hepatitis C - Pipeline by Beta Pharma Inc, H2 2017 Hepatitis C - Pipeline by Biocad, H2 2017 Hepatitis C - Pipeline by Bionor Pharma AS, H2 2017 Hepatitis C - Pipeline by Biotest Pharmaceuticals Corp, H2 2017 Hepatitis C - Pipeline by Biotron Ltd, H2 2017 Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Hepatitis C - Pipeline by Bolder Biotechnology Inc, H2 2017 Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H2 2017 Hepatitis C - Pipeline by Cocrystal Pharma Inc, H2 2017 Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by ContraVir Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by DEKK-TEC Inc, H2 2017 Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Hepatitis C - Pipeline by Genecode AS, H2 2017 Hepatitis C - Pipeline by GeneCure LLC, H2 2017 Hepatitis C - Pipeline by Gilead Sciences Inc, H2 2017 Hepatitis C - Pipeline by GinkgoPharma Co Ltd, H2 2017 Hepatitis C - Pipeline by GlaxoSmithKline Plc, H2 2017 Hepatitis C - Pipeline by ImmunoBiology Ltd, H2 2017 Hepatitis C - Pipeline by ImmunoClin Corp, H2 2017 Hepatitis C - Pipeline by Immunotope Inc, H2 2017 Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, H2 2017 Hepatitis C - Pipeline by JN-International Medical Corp, H2 2017 Hepatitis C - Pipeline by Johnson & Johnson, H2 2017 Hepatitis C - Pipeline by Karyopharm Therapeutics Inc, H2 2017 Hepatitis C - Pipeline by Kineta Inc, H2 2017 Hepatitis C - Pipeline by Ligand Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by Medivir AB, H2 2017 Hepatitis C - Pipeline by Merck & Co Inc, H2 2017 Hepatitis C - Pipeline by Microbio Co Ltd, H2 2017 Hepatitis C - Pipeline by MultiCell Technologies Inc, H2 2017 Hepatitis C - Pipeline by Novalex Therapeutics Inc, H2 2017 Hepatitis C - Pipeline by Novartis AG, H2 2017 Hepatitis C - Pipeline by NovaTarg Therapeutics Inc, H2 2017 Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 Hepatitis C - Pipeline by Pfenex Inc, H2 2017 Hepatitis C - Pipeline by Pfizer Inc, H2 2017 Hepatitis C - Pipeline by PharmaEssentia Corp, H2 2017 Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by Profectus BioSciences Inc, H2 2017 Hepatitis C - Pipeline by Replicor Inc, H2 2017 Hepatitis C - Pipeline by Rodos BioTarget GmbH, H2 2017 Hepatitis C - Pipeline by SomaGenics Inc, H2 2017 Hepatitis C - Pipeline by Sudershan Biotech Ltd, H2 2017 Hepatitis C - Pipeline by TaiGen Biotechnology Co Ltd, H2 2017 Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2017 Hepatitis C - Pipeline by Therapure Biopharma Inc, H2 2017 Hepatitis C - Pipeline by Theravectys SA, H2 2017 Hepatitis C - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017 Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H2 2017 Hepatitis C - Pipeline by Vertex Pharmaceuticals Inc, H2 2017 Hepatitis C - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017 Hepatitis C - Pipeline by Zylacta Corp, H2 2017 Hepatitis C - Dormant Projects, H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..1), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..2), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..3), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..4), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..5), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..6), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..7), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..8), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..9), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..10), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..11), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..12), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..13), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..14), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..15), H2 2017 Hepatitis C - Dormant Projects, H2 2017 (Contd..16), H2 2017 Hepatitis C - Discontinued Products, H2 2017 Hepatitis C - Discontinued Products, H2 2017 (Contd..1), H2 2017 Hepatitis C - Discontinued Products, H2 2017 (Contd..2), H2 2017 Hepatitis C - Discontinued Products, H2 2017 (Contd..3), H2 2017 Hepatitis C - Discontinued Products, H2 2017 (Contd..4), H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
